How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

33,212 results for

Double-Crush Syndrome

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

33061. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. (PubMed)

Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Twenty patients with irritable bowel syndrome due to food intolerance were randomized to either oral sodium cromoglycate or placebo in a double-blind cross-over trial. The study consisted of treatment with either sodium cromoglycate or placebo for 8 weeks, followed by the cross-over treatment for 8 further weeks. Patients were allowed to eat the offending foods during (...) the study. Eighteen patients completed the study. Analysis of patients' diary card scores showed a statistically significant difference in favour of sodium cromoglycate. There was a long carry-over effect in the active-placebo order group. Therefore oral sodium cromoglycate seems to be a useful treatment in patients with irritable bowel syndrome and proven food intolerance.

1991 Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Controlled trial quality: uncertain

33062. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. (PubMed)

Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. In order to test the ability of Ambroxol to improve the clinical course of respiratory distress syndrome and to reduce the incidence of complications a multicentre, randomized, placebo-controlled double-blind trial was conducted. Entry was limited to infants with a birth weight below 1500 g. A total of 179 neonates were enrolled, but 31 were later excluded because they had other diseases

1992 European journal of pediatrics Controlled trial quality: predicted high

33063. The feasibility of using a double blind experimental cross-over design to study interventions for sick building syndrome. (PubMed)

The feasibility of using a double blind experimental cross-over design to study interventions for sick building syndrome. Methodological problems have limited scientific investigation of the causes of and solutions for sick building syndrome. The feasibility of using an experimental double blind cross-over study to resolve many of these methodological problems was assessed in a pilot study. The experimental intervention was to vary the amount of outdoor air from 10 cubic feet per minute per (...) syndrome.

1992 Journal of Clinical Epidemiology Controlled trial quality: uncertain

33064. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. (PubMed)

Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. The efficacy and the tolerability of memantine (1-amino-3,5-dimethyladamantane hydrochloride, Akatinol Memantine, CAS 41100-52-1) were investigated in patients with mild to moderate dementia syndrome in a randomized two-centre placebo-controlled clinical study. The test substance was administered at a dose of 10 mg/d from day 1 to day 3 and then at a dose of 2 x 10 mg/d from day 4 (...) syndrome. Clinical and statistically relevant improvements in the dementia-induced disturbances were found on the both the psychopathological level (SCAG, CGI) and the behavioural level (GBS). On the performance level also, the ADL behaviour investigation detected a highly significant improvement in the quality of performance of instrumented activities of daily living under memantine. Also the time taken to carry out these tasks was significantly reduced in comparison with placebo.

1992 Arzneimittel-Forschung Controlled trial quality: uncertain

33065. Effect of intraarticular glycosaminoglycan polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double-blind trial comparing glycosaminoglycan polysulfate with placebo and quadriceps muscle exercises. (PubMed)

Effect of intraarticular glycosaminoglycan polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double-blind trial comparing glycosaminoglycan polysulfate with placebo and quadriceps muscle exercises. To compare the effects of intraarticular (IA) injections of glycosaminoglycan polysulfate (GAGPS) plus basic conservative treatment with the effects of placebo injections plus conservative treatment and with the effects of conservative treatment alone in patients (...) with chronic patellofemoral pain syndrome (PFPS).We treated 53 patients who presented with chronic PFPS in 1 knee, according to 1 of the 3 protocols, in a prospective, randomized, double-blind study. Basic conservative treatment consisted of a 6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral doses of nonsteroidal antiinflammatory drugs. Physiologic saline served as placebo for injection. During the 6-week treatment period, 5 injections were given 1 week

1992 Arthritis and rheumatism Controlled trial quality: uncertain

33066. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. (PubMed)

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. In 1985 and 1988 a positive effect of treatment of primary Sjögren's syndrome with hydroxychloroquine was reported in two small open studies. To investigate further the clinical and laboratory effects of hydroxychloroquine in primary Sjögren's syndrome a two year study was performed.The design of the study included a prospective, placebo controlled, two year double blind crossover trial in 19 (...) patients.A significant decrease in IgG and IgM and a tendency for a decrease in the erythrocyte sedimentation rate (ESR) during treatment with hydroxychloroquine compared with treatment with placebo were found. No beneficial clinical effect of the use of hydroxychloroquine as expressed in preference for treatment with hydroxychloroquine or placebo with regard to symptoms and signs of primary Sjögren's syndrome could be shown, however, nor any relevant change in tear gland activity and sequelae

Full Text available with Trip Pro

1993 Annals of the rheumatic diseases Controlled trial quality: uncertain

33067. [Tetrazepam in the treatment of acute cervical syndrome. Randomized double-blind pilot study comparing tetrazepam and placebo]. (PubMed)

[Tetrazepam in the treatment of acute cervical syndrome. Randomized double-blind pilot study comparing tetrazepam and placebo]. In a double-blind study, 20 ambulatory patients with acute painful restriction of mobility of the cervical spine and overall marked impairment were treated for seven days with tetrazepam (150 mg or a lower dose from the third day onward) or placebo. Paracetamol was permitted in addition if required. Test criteria: The main criterion of efficacy was a summed score

1993 Fortschritte der Medizin Controlled trial quality: uncertain

33068. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome. (PubMed)

Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome. We conducted a randomized, double-blind, placebo-controlled crossover study of folinic acid therapy (dl-Leucovorin, 15 mg/day) or placebo for males with Fragile X (fra(x)) syndrome. Twenty-one patients were enrolled in the study. The treatment periods were 3 months in length. Patients were followed with chemistry panels and complete blood counts. No differences between placebo

1992 American journal of medical genetics Controlled trial quality: uncertain

33069. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. (PubMed)

Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. To evaluate the potential benefit of immunologic therapy with dialyzable leukocyte extract and psychologic treatment in the form of cognitive-behavioral therapy (CBT) in patients with chronic fatigue syndrome (CFS).Immunologic and psychologic treatments were administered to 90 adult patients who fulfilled diagnostic criteria for CFS in a double-blind, randomized, and placebo

1993 The American journal of medicine Controlled trial quality: uncertain

33070. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. (PubMed)

Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. In a double-blind randomized crossover trial, oxycodone or placebo was given in divided night-time doses to 11 patients with idiopathic restless legs syndrome (RLS) for 2 weeks prior to appropriate polysomnographic studies. Under double-blinded conditions, patients were asked to do daily ratings of their leg sensations, motor restlessness and daytime alertness on a 1-4 (...) scale for the 2 weeks prior to the polysomnographic studies and for the nights of the polysomnographic studies as well. Leg sensations (p < 0.009), motor restlessness (p < 0.006) and daytime alertness (p < 0.03) were significantly improved on oxycodone as compared to baseline or placebo. Patients were studied polysomnographically under double-blinded conditions for 2 nights in each phase of the protocol. On an average dose of 15.9 mg oxycodone (equivalent to approximately three 5-mg tablets

1993 Sleep Controlled trial quality: uncertain

33071. Double-blind placebo-controlled trial of corticosteroids in children with postpericardiotomy syndrome. (PubMed)

Double-blind placebo-controlled trial of corticosteroids in children with postpericardiotomy syndrome. The objective of this study was to assess the efficacy of corticosteroids in hastening the recovery of children with postpericardiotomy syndrome, using a randomized double-blind placebo-controlled trial in a tertiary care referral center for pediatric cardiology and cardiac surgery. Twenty-one children, 6 months of age or older (mean age 3.9 years) with postpericardiotomy syndrome following (...) , p = 0.03). A trend to faster resolution of all symptoms and signs was seen in the prednisone-treated group but this was not associated with earlier hospital discharge. Enlargement of pericardial effusion was seen in two children treated with steroids. No complications of treatment were encountered. Prednisone hastens the recovery of children with postopericardiotomy syndrome. Pericardial effusions may increase in size despite the use of corticosteroids.

1995 Pediatric Cardiology Controlled trial quality: predicted high

33072. Helium-oxygen mixture in respiratory distress syndrome: a double-blind study. (PubMed)

Helium-oxygen mixture in respiratory distress syndrome: a double-blind study. In a randomized, controlled trial, the lungs of infants with respiratory distress syndrome were ventilated with either a helium-oxygen mixture or a nitrogen-oxygen mixture. In the helium-oxygen group, infants required a lower inspired oxygen concentration and a shorter duration of ventilation. There were also fewer deaths and fewer cases of bronchopulmonary dysplasia in the helium-oxygen group.

1993 The Journal of pediatrics Controlled trial quality: uncertain

33073. Chlormezanone in primary fibromyalgia syndrome: a double blind placebo controlled study. (PubMed)

Chlormezanone in primary fibromyalgia syndrome: a double blind placebo controlled study. Primary fibromyalgia syndrome (PFS) is a common condition that often proves resistant to health interventions. Chlormezanone combines corrective effects on disturbed sleep with muscle-relaxant properties, and therefore could be of potential benefit in PFS. Forty-two female patients with PFS (mean age 49, range 24-72 years) were randomly and blindly allocated either chlormezanone 400 mg nocte or placebo

1993 British journal of rheumatology Controlled trial quality: uncertain

33074. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. (PubMed)

A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. To determine if ketoconazole, a thromboxane A2 synthetase inhibitor, given within the first 24 hrs after diagnosis and arrival in the intensive care unit (ICU) would decrease the frequency of adult respiratory distress syndrome in the septic patient population.Prospective, randomized, double-blind, placebo-controlled study.Twelve-bed (...) % immature cells; c) positive blood culture; d) known or strongly suspected source of infection from which a known pathogen was cultured.Patients were randomized to receive either ketoconazole (400 mg) or placebo in a double-blind fashion as early as possible and in < 24 hrs after surgical ICU admission or after the diagnosis of sepsis was established.Adult respiratory distress syndrome (ARDS) was diagnosed if the following criteria were met: a) intrapulmonary shunt of > 20%, or a PaO2/FIO2 ratio

1993 Critical care medicine Controlled trial quality: predicted high

33075. Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients. (PubMed)

Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients. Irreversible hyposalivation is a common sequela of Sjögren's syndrome and may lead to a decreased quality of the patient's life. The aim of this study was to evaluate the efficacy and therapeutic value of mucin-containing lozenges in reducing patients' complaints of hyposalivation. In a double-blind crossover trial in 42 patients with Sjögren's (...) syndrome, the efficacy and therapeutic value of both a mucin-containing and placebo lozenge were assessed by means of self-administered questionnaires, which had to be completed before and after the use of each type of lozenge for a period of 2 weeks. Seventy-six percent of the patients preferred the mucin lozenge, 10% preferred the placebo, and 14% had no preference. In reducing patients' complaints, sucking the mucin lozenge resulted in a larger improvement of the total pattern of complaints

1993 Oral surgery, oral medicine, and oral pathology Controlled trial quality: uncertain

33076. Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial. (PubMed)

Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial. Thirty-seven male alcoholics admitted electively for detoxification were randomized to treatment with either diazepam or propranolol. Subjects were comparable both in age and in duration and quantity of alcohol consumed. Admission laboratory parameters did not distinguish between the groups. Eleven subjects required no medication to control withdrawal signs/symptoms. Both groups (...) still remain the "gold standard" for management of the withdrawal syndrome.

1994 The American journal of drug and alcohol abuse Controlled trial quality: uncertain

33077. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. (PubMed)

Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. In a double-blind study 40 abstinent hospitalized male patients with an alcoholic organic brain syndrome (OBS; ICD 9: 291.2) were treated for 6 weeks with either placebo or 200 mg modafinil b.i.d. Modafinil (CRL 40476) is a vigilance-promoting, putative central alpha 1-adrenergic agonist with a pharmacological profile quite

1993 Neuropsychobiology Controlled trial quality: uncertain

33078. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. (PubMed)

Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. To evaluate the efficacy of alprazolam in the treatment of premenstrual syndrome.A randomized, double-blind, placebo-controlled, crossover trial of alprazolam during eight menstrual cycles.Outpatient clinic at the National Institute of Mental Health, Bethesda, Md.Twenty-two women with prospectively confirmed premenstrual syndrome entered this study. All subjects were either self-referred or were (...) Inventory Scale. The Beck Depression Inventory ratings demonstrated a statistically (F1,19 = 7.1, P < .05), but not clinically, significant improvement in depressive symptoms during alprazolam administration compared with placebo.Our findings do not support alprazolam as a uniformly effective treatment for the symptoms of premenstrual syndrome.

1993 Archives of general psychiatry Controlled trial quality: predicted high

33079. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. (PubMed)

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. We studied the effects of intravenous immunoglobulin (IVIg) in 12 patients with motor neuron syndromes associated with high titers of anti-GM1 antibodies. Five of the patients had conduction blocks. The study design was a double-blind, placebo-controlled, crossover trial with IVIg (0.4 g/kg body weight per day injected for 5 consecutive days

1994 Neurology Controlled trial quality: uncertain

33080. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. (PubMed)

Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Although its etiology is unknown, it has been hypothesized that premenstrual syndrome (PMS) is linked to a deficiency of central serotoninergic activity. In the present study, we evaluated the effect of fluoxetine, a specific serotonin uptake inhibitor, on PMS symptoms.Following extensive screening, including several psychological inventories, eight women with severe persistent PMS (...) participated in a 6-month double-blind, placebo-controlled, crossover study which included three months each of daily fluoxetine 20 mg or placebo, administered in a randomized order. Symptoms were evaluated using the Calendar of Premenstrual Experiences and other psychometric measures.Compared with placebo, treatment with fluoxetine was associated with an improvement in PMS symptoms as judged by highly significant decreases in behavioral (P less than .005), physical (P less than .05), and total (P less

1992 Obstetrics and Gynecology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>